Intra-Cellular Therapies(ITCI) - 2020 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company recorded net product sales of CAPLYTA for Q1 2020 of approximately $882,000, with no net product sales reported in the same period of 2019 [37] - Research and development (R&D) expenses for Q1 2020 were $16 million, down from $25 million in Q1 2019, primarily due to lower clinical and non-clinical costs for lumateperone [37] - Sales, general and administrative (SG&A) expenses were $34.1 million for Q1 2020, compared to $11.7 million for the same period in 2019, reflecting an increase of $22.4 million due to higher selling-related costs and general administrative costs [38][39] - Cash, cash equivalents, restricted cash, and investment securities totaled $450.4 million at March 31, 2020, compared to $224 million at December 31, 2019 [40] Business Line Data and Key Metrics Changes - CAPLYTA's launch was successfully executed despite the COVID-19 pandemic, with approximately 240 neuroscience specialists engaging healthcare providers [10][14] - The promotion of CAPLYTA began the week of March 30th, with significant progress in discussions with payers regarding market access and reimbursement [14][15] - The company achieved formulary coverage for 90% of covered lives under Medicare Part D plans, including unrestricted coverage by CVS SilverScript [15][24] Market Data and Key Metrics Changes - The company is focusing on approximately 23,000 healthcare providers who account for 80% of branded antipsychotic schizophrenia prescriptions [21] - The initial patient experience with CAPLYTA has been positive, aligning with the documented clinical efficacy and safety profile [27] Company Strategy and Development Direction - The company remains committed to addressing the high unmet medical need for new treatment options for schizophrenia and other serious mental illnesses [9] - The company is adapting its commercial strategy to a virtual environment, enhancing digital outreach and medical education programs [20][27] - The company anticipates broad access for CAPLYTA across payer channels to be fully established by year-end [26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the disruptions caused by COVID-19 but emphasized the company's adaptability and successful execution of CAPLYTA's launch [10] - The company expects prescription performance to accelerate as sales force operations normalize throughout the year [27] - Management expressed confidence in CAPLYTA becoming a leading treatment choice for adult patients with schizophrenia [23] Other Important Information - The company ended Q1 2020 with $450 million in cash and investments, positioning it for continued development and commercialization of novel drugs [17] - The company is advancing multiple clinical development programs, including lumateperone for bipolar depression and ITI-214 for chronic systolic heart failure [34][36] Q&A Session Summary Question: Feedback on CAPLYTA's differentiation and patient targeting - Management noted positive feedback from payers and prescribers regarding CAPLYTA's safety and tolerability profile, with a broad target population of adult patients not adequately treated [42][44] Question: Impact of telemedicine on psychiatric care - Management confirmed a shift to telemedicine in psychiatry, effectively treating patients during the pandemic [47] Question: Filing strategy for bipolar indication - Management confirmed plans to use results from multiple studies, including 401, 404, and 402, for potential filing with the FDA [48][49] Question: Monitoring side effects through telemedicine - Management indicated that telepsychiatry has been effective for monitoring side effects, with no significant impact on the ongoing studies [62][63] Question: Expected inventory build and buying patterns - Management does not anticipate unusual inventory patterns, with efficient supply chain operations in place [89] Question: Prescribing dynamics and payer blocking - Management stated that it is too early to comment on payer blocking of scripts, but they are pleased with progress on access and coverage determinations [92][95]